The health hub in Nice is advancing towards excellence by acquiring a unique cell sorting platform, CytoMed, which will play a key role in developing personalized medicine for the benefit of all patients.
This equipment, valued at nearly 1.3 million euros, was acquired thanks to funding from the General Council of the Alpes-Maritimes, the European Union (via the European Regional Development Fund), the Provence-Alpes-Cรดte d’Azur region, and Inserm.
Its operation is managed by IRCAN, the Institute for Research on Cancer and Aging, within the framework of the Platform for Experimental Exploration in Personalized Cancer and Aging Medicine (PEMED-PCV), which is open to the French and international medical-scientific community.
IRCAN is a research laboratory established on January 1, 2012, jointly by the University of Nice Sophia Antipolis, CNRS, and Inserm. The institute also works closely with the Antoine Lacassagne Cancer Center and the CHU of Nice.
The research conducted at IRCAN, led by Prof. Eric GILSON, a Professor of Cell Biology at the University of Nice Sophia Antipolis, aims to closely understand the mechanisms of aging and the deregulations that cause cancers of different tissue origins, certain forms of diabetes, kidney failure, neurodegenerative diseases, and cardiovascular diseases.